HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--June 27, 2006--Nymox Pharmaceutical Corporation (NASDAQ:NYMX - News) is pleased to report that the Company’s new updated Safety Committee review of safety data for its ongoing multi-center U.S. Phase 2 trial of NX-1207 has revealed no serious drug side effects. The entire cohort of enrolled subjects have now all completed their drug dosing in the trial. NX-1207 is Nymox’s lead drug candidate for the treatment of benign prostatic hyperplasia (BPH).
